Studies platelet activity in lupus and other immune diseases
Observes platelet activity in adults with lupus and related autoimmune diseases.
Key facts
- Who runs it
- University Hospital, Strasbourg, France
- Where
- Strasbourg, FranceSee the site
- Trial code
- Registry title
- ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUS
- Status
- Recruiting
- People taking part
- 450 people, planned
- Started
- 9 Jan 2024
- Expected to end
- 9 Jan 2029
- Type of study
- Observational
- Record updated
- 19 September 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 70 with a confirmed diagnosis of lupus or another autoimmune disease such as scleroderma, vasculitis, myositis, Sjögren's syndrome or rheumatoid arthritis.
- Age
- 18 to 70 years
- Sex
- All sexes can join.
- Disease stage
- Confirmed diagnosis of at least one of these: systemic lupus erythematosus, systemic scleroderma, ANCA vasculitis, inflammatory myositis, Gougerot-Sjögren syndrome or rheumatoid arthritis, meeting the listed classification criteria.
Main reasons for not taking part
- Being in an exclusion period from a previous or current study
- Not able to give informed consent (emergency or immediate life-threatening situation)
- Being under court protection
- Being under guardianship or curatorship
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Patients between 18 and 70 years of age
- Patient affiliated to a health insurance scheme (beneficiary or beneficiary's beneficiary)
- Patient able to understand the aims and risks of research
- Patient having signed and dated an informed consent form
- Patient for whom the diagnosis of at least one of the following pathologies has been confirmed:
- Systemic lupus erythematosus meeting ACR/EULAR 20195 classification criteria
- Systemic scleroderma meeting ACR/EULAR 20136 classification criteria
- ANCA vasculitis according to EULAR/ACR 2022.7-9 classification criteria
- Inflammatory myositis according to EULAR/ACR 201710 classification criteria
- Gougerot-Sjögren syndrome according to EULAR/ACR 2016 classification criteria11
- Rheumatoid arthritis according to ACR/EULAR 201012 classification criteria
Who cannot take part
- Patient in exclusion period (determined by a previous or current study)
- Inability to give patient informed consent (patient in emergency or immediate life-threatening situation)
- Patient under court protection
- Patient under guardianship or curatorship
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in France
- Hopitaux Universitaires de Strasbourg - Hopital de Hautepierre - Service de rhumatologieStrasbourg, FranceContact: Marc SCHERLINGERTaking people
About the trial
What the trial wants to find out
Blood platelets, well known for their role in hemostasis, are abnormally activated in patients suffering from systemic lupus erythematosus (SLE), but also from other immunomediated diseases (scleroderma, vasculitis, myositis, Gougerot-Sjögren's and rheumatoid arthritis) in cases of high disease activity. Once activated, platelets express adhesion molecules such as P-selectin on their surface, enabling them to interact physically with immune cells. In a recent work, we identified that activated platelets from lupus patients interact with regulatory T cells and block their regulatory function, thus participating in the deregulated activation of the immune system in SLE. In addition, inhibition of platelet-immune cell interactions by an anti-P-selectin antibody improved LES symptoms in two mouse models.
Read full original descriptionShow less
The aim of this work is to investigate other potential platelet-immune cell interactions in patients with SLE, in comparison with other autoimmune diseases (systemic scleroderma, ANCA vasculitides, inflammatory myositis, Gougerot-Sjögren syndrome and rheumatoid arthritis).
This study could lead to a better understanding of the role of platelets in the pathophysiology of autoimmune diseases, identify new biomarkers of activity, and assess the potential of new therapeutic avenues in these diseases, such as platelet targeting.
The group in the trial
- systemic lupus erythematosus patients
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUS
- Plain-language title
- Studies platelet activity in lupus and other immune diseasesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06593041, who can take part
- Record updated
- 19 September 2024